RedHill Biopharma Secures Key Chinese Patent for COVID-19 Treatment RHB-107

RedHill Biopharma ( (RDHL) ) has shared an announcement.

On April 28, 2025, RedHill Biopharma announced that the China National Intellectual Property Administration has allowed a key patent application for RHB-107, a proprietary oral treatment for COVID-19. This patent strengthens RedHill’s strategic position in the global COVID-19 therapeutic market, expected to be worth over $3 billion in 2025, and expands its patent footprint in Asia. RHB-107 has shown promising results in a U.S. Phase 2 study, demonstrating a significant reduction in hospitalization and severe symptoms of COVID-19. The patent provides broad protection for RHB-107, enhancing its potential as a novel, broad-acting antiviral that could complement existing treatments like Pfizer’s Paxlovid.

Spark’s Take on RDHL Stock

According to Spark, TipRanks’ AI Analyst, RDHL is a Underperform.

RedHill Biopharma faces significant financial and operational challenges. The most significant factor affecting the score is its financial performance, highlighting operational inefficiencies and high leverage. Technical analysis indicates bearish momentum, and the absence of valuation metrics such as P/E ratio and dividend yield further complicates the investment outlook.

To see Spark’s full report on RDHL stock, click here.

More about RedHill Biopharma

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology, primarily in the U.S. The company promotes Talicia, an FDA-approved drug for Helicobacter pylori infection, and has several late-stage clinical development programs targeting various conditions, including COVID-19, cancer, and gastrointestinal diseases.

YTD Price Performance: -62.34%

Average Trading Volume: 228,721

Technical Sentiment Signal: Buy

Current Market Cap: $3.07M

See more data about RDHL stock on TipRanks’ Stock Analysis page.